Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: a meta-analysis

Huan Zhang, Chengqi Zhang, Cuicui Sun, Qiong Zhang2023 · DOI

Abstract

Chronic renal failure (CRF) is a clinical syndrome characterized by progressive renal function decline, leading to significant morbidity and mortality worldwide. In China, the prevalence of chronic kidney disease is approximately 10.8%. While conventional Western medical treatments (CT) exist, they often fail to halt disease progression. Jinshuibao (JSB), a traditional Chinese patent medicine derived from Cordyceps sinensis, is frequently used as an adjuvant therapy. This protocol outlines a systematic review and meta-analysis designed to evaluate the efficacy and safety of JSB in treating CRF among Chinese patients, providing evidence-based guidance for clinical practice.

Introduction

Chronic Renal Failure (CRF) represents a major global public health challenge, currently ranked as the sixth leading cause of death worldwide. The condition involves a decline in glomerular filtration rate, metabolite retention, and systemic imbalances in electrolytes and acid-base levels. Despite advances in modern medicine, current interventions—such as blood pressure management and dietary restrictions—primarily focus on slowing progression rather than recovery.

In China, traditional Chinese medicine (TCM) is often integrated with Western protocols. Jinshuibao (JSB) is one such intervention, noted for its potential to modulate immune response and reduce inflammation. However, existing clinical data on JSB is fragmented. This study aims to synthesize available evidence through a rigorous meta-analysis of randomized controlled trials (RCTs).

Methodology

The research follows a pre-defined protocol registered to ensure transparency and minimize bias.

The study protocol is registered with INPLASY.

Search Strategy and Inclusion Criteria

The investigators will conduct a comprehensive search across eight databases, including PubMed, EMBASE, the Cochrane Library, and major Chinese repositories like CNKI and Wanfang, for studies published through March 2023. Inclusion is restricted to RCTs comparing JSB plus conventional treatment against conventional treatment alone in patients diagnosed with CRF.

Statistical Analysis

Data synthesis will be performed using Review Manager (Revman) 5.4. Heterogeneity will be assessed using the $\chi^2$ test and $I^2$ statistic. A random-effects model will be employed if $I^2 \geq 50\%$; otherwise, a fixed-effect model will be used. Subgroup analyses are planned based on treatment duration (4, 8, and 12 weeks) to identify temporal efficacy patterns.

Outcome Measures

The study evaluates efficacy through multiple lenses:

  1. Primary Outcome: Total effective rate of treatment.
  2. Renal Function Markers: Serum creatinine (Scr), blood urea nitrogen (BUN), and uric acid (UA).
  3. Inflammatory Indices: Levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP).

By including microinflammatory indices, the researchers aim to investigate whether JSB’s benefits are linked to a reduction in systemic inflammation, a known driver of renal decline.

Discussion and Limitations

This meta-analysis seeks to bridge the gap between traditional Chinese medicine and evidence-based clinical standards. By applying Western statistical rigors to JSB, the study could validate its role as a standard adjuvant therapy.

However, several limitations are anticipated. The quality of the meta-analysis is inherently dependent on the quality of the source RCTs; risks of bias in blinding or allocation concealment in original trials may affect the strength of the conclusions. Furthermore, as the study focuses on Chinese populations, the generalizability of the findings to other ethnic groups remains to be determined. Future research should involve multi-center international trials to explore the molecular mechanisms of JSB more deeply.

Note: This paper describes a study protocol. Results are pending the completion of the meta-analysis.

Summary updated

Abstract

Review question / Objective: Our aim is to systematically evaluate the efficacy of JSB for the treatment of CRF in Chinese patients, and to provide evidence-based medical advice for clinical practice.Condition being studied: Chronic renal failure (CRF) is a clinical syndrome with progressive renal function decline until failure on the basis of various chronic kidney diseases.The main clinical manifestations are the decline of glomerular filtration rate, retention of metabolites, disorders of water and electrolyte and imbalance of acid-base balance.[1-2] It has many complications and poor prognosis, which seriously affects the quality and the span of life in patients.[3]The incidence of CRF is increasing year by year and has b e c o m e a m a j o r p u b l i c h e a l t h p ro b l e m w o r l d w i d e .[ 4 ] Epidemiological survey shows that chronic kidney disease has become the sixth cause of death in the world.[5]The prevalence rate of chronic kidney diseases among American adults is high at 15.1%, and the prevalence of chronic kidney diseases in China is about 10.8%.[6]At present, there is no effective treatment for CRF all over the world, and the only interventional treatment can be carried out, which cannot completely prevent the development of the disease.Therefore, it is particularly important to actively seek effective therapeutic drugs to alleviate CRF and delay the renal failure.Chronic renal failure (CRF) is a clinical syndrome with progressive renal function decline until failure on the basis of various chronic kidney diseases.
BibTeX
@misc{zhang2023efficacy,
  author = {Huan Zhang and Chengqi Zhang and Cuicui Sun and Qiong Zhang},
  title = {{Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: a meta-analysis}},
  year = {2023},
  doi = {10.37766/inplasy2023.5.0105},
}
Figure